Nowadays minimal residual disease (MRD) and log-reduction of leukemic cells are poorly investigated in elderly patients with acute myeloid leukemia (AML) treated with hypometilating agents (HMAs). Studies focusing on MRD in elderly AML patients who received HMAs are scant and devoid of rigorous criteria for both enrollment and monitoring. Log-reduction has never been investigated in these patients. Thus, the purpose of our study was to compare the prognostic impact of MRD and log-reduction of leukemic cells at the optimal time of assessment in older AML patients.

中文翻译：

---

流式细胞仪检测白血病细胞和微小残留病的对数减少是老年急性髓细胞白血病患者临床结果的有效预测指标

如今，在用低代谢药物 (HMA) 治疗的急性髓性白血病 (AML) 老年患者中，很少研究微小残留病 (MRD) 和白血病细胞的对数减少。针对接受 HMA 的老年 AML 患者的 MRD 的研究很少，而且缺乏严格的入组和监测标准。从未在这些患者中研究过对数减少。因此，我们研究的目的是在老年 AML 患者的最佳评估时间比较 MRD 的预后影响和白血病细胞对数减少的影响。